[5] Early adjuvant therapy -- replacing tamoxifen therapy with aromatase inhibitor therapy during the first 5 years after surgery; Early sequential adjuvant therapy -- sequencing of tamoxifen and ...

Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

Basel: Novartis has announced that it has entered into a global license and collaboration agreement with PTC Therapeutics for ...

Novartis (NVS) announced that the European Commission, EC, has approved Kisqali in combination with an aromatase inhibitor, AI, for the ...

Novartis’ Kisqali (ribociclib) has been approved by the European Commission (EC) to reduce the risk of disease recurrence in ...

The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat ...

Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...

Winrevair was approved to treat PAH WHO Group 1 in the United States in March based on data from the STELLAR study.

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node ...

Leading Victorian trainer Patrick Payne says he has been left shocked after one of his horses returned a pair of positive swabs and was banned from the track for 12 months. RV said a stewards' ...

Novartis announced today that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone ...